The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) and believe this therapy will have broad application in humans.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382866 | PMC |
| http://dx.doi.org/10.4161/onci.18804 | DOI Listing |
Publication Analysis
Top Keywords
histone deacetylase
8
deacetylase inhibitors
8
combination histone
4
inhibitors immune-stimulating
4
immune-stimulating antibodies
4
antibodies potent
4
potent anti-cancer
4
anti-cancer effects
4
effects immunotherapy
4
immunotherapy treat
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!